Clinical
 | JDP Successfully Completes Its Initial Phase 3 Clinical Trial of JDP-205 in Patients with Acute Urticaria Associated with an Acute Allergic Reaction - JDP Therapeutics Inc., a privately held specialty pharmaceutical company, is pleased to announce that the Company has successfully completed the initial Phase 3 clinical trial (ETTAU-02) on its lead candidate JDP-205 in patients with acute urticaria associated with an acute allergic reaction. The result of this study has met and/or outperformed every parameter designed for this trial. » By GCL PRL, created on Jan. 9 2015 In Press Releases and Company Profiles |
